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bstract
In clinical trials, the specificity of the disease endpoint is critical to an accurate estimate of vaccine efficacy. We used a logistic regression
odel to analyse parasite densities among children before and after treatment with antimalarials, in order to estimate the impact that clearing
symptomatic parasitaemia had on the specificity of the endpoint of febrile malaria. The malaria attributable fever fraction was higher
fter antimalarial treatment (i.e. fever and parasitaemia were more likely to be causally related), implying that drug treatment prior to
onitoring decreased the misclassification of febrile malaria. In intervention studies with febrile malaria as an endpoint, clearing asymptomatic
arasitaemia increases the study’s power more effectively than raising the threshold parasitaemia.
2007 Elsevier Ltd.
eywords: Plasmodium falciparum; Malaria attributable fraction; Specificity; Febrile malaria; Definition
a
b
p
1
o
p
e
a
m
Open access under CC BY license.. Introduction
Field trials of candidate malaria vaccines often use febrile
alaria as an endpoint [1–4]. The case definition of febrile
alaria usually requires a measured temperature and par-
sitaemia. In endemic areas non-malarial fever is common
n young children, and by chance frequently coincides with
symptomatic parasitaemia [5]. Including these cases in the
ndpoint thus reducing the specificity of the case definition
or febrile malaria. It is possible to increase the specificity by
dopting a threshold parasitaemia, on the basis that asymp-
omatic parasitaemia tends to be at a lower density than febrile
alaria. However, since the distributions of asymptomatic
arasitaemia density and febrile malaria density overlap, this
hreshold is necessarily a compromise between sensitivity
∗ Corresponding author. Tel.: +254 720 851 442; fax: +254 415 22396.
E-mail address: pbejon@kilifi.kemri-wellcome.org (P. Bejon).
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Open access under CC BY license.nd specificity. In epidemiological studies and clinical trials
oth sensitivity and specificity are desirable to maximise the
ower of the study [6–8].
.1. Clearing asymptomatic parasitaemia
Treatment of asymptomatic parasitaemia is done for vari-
us reasons. It is an integral part of the strategy of intermittent
reventative treatment [9]. In vaccine trials with the primary
ndpoint of time to infection, pre-surveillance clearance of
symptomatic infection is essential [10,11]. Where the pri-
ary endpoint is febrile or severe disease this would not be
ecessary, and some data suggest that efficacy might be bet-
er measured without pre-treatment [4]. Since asymptomatic
arasitaemia complicates the definition of febrile malaria, it
s possible that clearing asymptomatic parasitaemia might
lter the case definition of febrile malaria, and may result in
more specific definition without any loss in sensitivity.
cine 25
1
a
t
r
a
i
l
a
t
fi
a
l
c
t
i
[
e
t
c
1
t
c
p
c
r
i
p
s
t
d
2
2
s
m
w
r
a
t
v
2
a
b
c
w
2
r
d
p
t
m
f
l
n
v
c
a
t
3
t
c
m
(
2
fi
l
f
d
t
a
w
t
t
t
i
e
w
a
r
a
2
s
T
n
c
2
eP. Bejon et al. / Vac
.2. Malaria attributable fever fractions
The malaria attributable fever fraction (MAFF) is defined
s the fraction of fevers that can be attributed to malaria infec-
ion (i.e. the remainder of fevers outside this fraction are the
esult of coincident non-malarial fever and asymptomatic par-
sitaemia). While it may not be possible to determine which
ndividuals are “true” cases of febrile malaria, and so calcu-
ate this fraction by an arithmetically calculated numerator
nd denominator, using a logistic regression model allows
he MAFF in a population to be estimated [12]. This method
ts parasite density to the probability of febrile malaria in
logistic regression model. Once MAFFs have been calcu-
ated at different ranges of parasitaemia, it is then possible to
alculate the sensitivity and specificity of different parasite
hresholds. This has been used to generate case definitions
n different age groups and malaria transmission intensities
13–15]. Here, we used this approach to examine the hypoth-
sis that clearing asymptomatic parasitaemia would increase
he specificity of the case definition of clinical malaria in a
ohort of children under longitudinal surveillance.
.3. The impact of speciﬁcity of the endpoint
The specificity of the endpoint is critical to a trial’s ability
o correctly estimate vaccine efficacy. If a vaccine is effica-
ious against febrile malaria, but not against asymptomatic
arasitaemia, then including cases of non-malarial fever that
oincide with asymptomatic parasitaemia in the endpoint will
educe the apparent efficacy of the vaccine. Our objective
n this analysis was to compare infections before and after
arasite clearance was given, and so calculate the MAFF,
ensitivity, and specificity at various parasite densities. This
hen allows the relative power of studies with and without
rug clearance to be estimated.
. Methods
.1. Study participants
Four hundred and five children, aged 1–6-years-old (inclu-
ive), were randomised for either an experimental prime boost
alaria vaccine or control vaccination (rabies). The children
ere healthy, and resident in Junju, within Kilifi District, a
ural area of coastal Kenya. The process of randomization
nd vaccination is detailed elsewhere [3]. Since the vaccina-
ion was not efficacious, no adjustment has been made for
accination group.
.2. Blood samples and clearance of parasitaemiaCross-sectional surveys to examine peripheral blood par-
sitaemia were conducted at recruitment (January 2005)
efore any antimalarial treatment was given. After three vac-
inations and antimalarial treatment, cross-sectional surveys
i
o
t
w(2007) 8198–8202 8199
ere conducted 2 weeks after antimalarials were given (May
005), then after 3 months in September 2005 (end of the
ainy season) and after 8 months in January 2006 (during the
ry season). Antimalarial treatment to clear asymptomatic
arasitaemia was given 1 week after the final vaccina-
ion, using 7 days of directly observed dihydroartemisinin
onotherapy (2 mg/kg on the first day, followed by 1 mg/kg
or 6 days). Four hundred and five children received at
east one vaccination, and of these 387 finished the vacci-
ation course and completed at least one further monitoring
isit for malaria episodes. Three hundred and sixty children
omplied with the 7 days observed artesunate and were par-
site negative 2 weeks later. Analysis here is restricted to
hese 360 children. Ninety-four fevers were assessed in the
months before clearance of asymptomatic parasitaemias
reatment, and 353 in the 9 months after clearance. Further
ross-sectional surveys were taken 3 months post-drug treat-
ent (early August 2005) and 9 months post-drug treatment
January 2006).
.3. Monitoring for malaria episodes
Children were seen weekly by field workers, and blood
lms made when the temperature was >37.5◦. Field workers
ived in the study area, and parents brought their children
or assessment between regular weekly visits if the child
eveloped fever. Treatment for episodes of malaria was with
he Government of Kenya recommended first line treatment,
rtemether–lumefantrine. When the mother reported the child
as hot, but an objectively elevated temperature was not iden-
ified, blood films and rapid testing was not performed, but
he field worker returned to the child a further three times in
he next 24 h. Rapid testing and blood films were performed
f the temperature was elevated on any of these visits. Par-
nts brought their children for assessment in between regular
eekly visits if they thought the child had developed fever,
nd the child was assessed as above. Field workers were
ecruited from the villages in which the study was conducted,
nd so were readily accessible to the parents.
.4. Laboratory procedures
Blood films were examined in duplicate by two micro-
copists, and examined a third time if there was a discrepancy.
he results of blood films at cross-sectional bleeds were
ot immediately available, and asymptomatic parasitaemic
hildren were not treated unless they developed fever.
.5. Analysis
The parasite densities from the cross-sectional survey and
pisodes of febrile malaria before drug treatment were used
n a logistic model to relate parasite density to the likelihood
f fever. The data are analysed by three time periods. The pre-
reatment period included 6–7 weeks of dry weather and 6–7
eeks of rains. The post-treatment period was analysed sep-
8 cine 25 (2007) 8198–8202
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Fig. 1. The sensitivity, specificity and malaria attributable fever fraction
curves for varying parasitaemia thresholds are shown for subjects before
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rately for the first 12 weeks of rains, and for the subsequent
4 weeks of dry weather. The pre-treatment analysis used
alaria episodes between January 2005 and May 2005, and
he cross-sectional bleed from January 2005. Vaccinations
ere given between January and May 2005, and antimalar-
al drug treatment given in May 2005. The post-treatment
ainy season analysis used malaria episodes between May
005 and September 2005, and the cross-sectional bleed from
eptember 2005. The post-treatment dry season analysis used
alaria episodes between September 2005 and January 2006,
nd the cross-sectional bleed from January 2006.
The method for deriving malaria attributable fever frac-
ions (MAFFs) has been described previously [5]. Briefly, the
ogistic regression model is used (logit(p) = a + bxτ , where
is the probability of fever, x the density of parasitaemia
nd τ is the power function of the parasite density which
aximises the likelihood estimation for the different time
oints). The coefficient b can then be used to estimate the
isk of febrile malaria in individual children, and the aver-
ge risk of malaria among a group of children with fever
ives the fraction of those children whose fever was a direct
esult of malaria (i.e. the malaria attributable fever fraction,
AFF). This calculation can be repeated after selecting chil-
ren above a threshold parasitaemia, and used to calculate
he sensitivity and specificity of threshold values for parasite
ensity.
Separate analyses were conducted by vaccination status.
AFFs were not different by vaccination group, and vac-
ination had no effect on frequency of malaria episodes or
arasitaemia [3]. The combined analysis is presented here.
. Results
In the pre-treatment cross-sectional survey (January
005), 71% of children were parasitaemic. 2 weeks after
rug treatment 2% were parasitaemic, but 3 months (Septem-
er 2005, post-treatment rainy season) and 9 months later
January 2006, post-treatment dry season), 27% and 33% of
hildren were parasitaemic, respectively.
.1. Parasitaemias during febrile episodes varied before
nd after drug clearance
Before drug clearance of asymptomatic parasitaemia, 47
f 121 (38%) of children with fever had no parasitaemia,
ompared with 75 of 182 (41%) during the rainy season post-
rug clearance (Fig. 1), and 70 of 124 (56%) in the next 24
eeks of the dry season post-treatment.
.2. Speciﬁcity, sensitivity and malaria attributable
ractionsA logistic model was fitted to the data as described previ-
usly [5]. The sensitivity, specificity and malaria attributable
ever fractions (MAFFs) given by using different para-
e
c
earasite clearance, and for rainy and dry season follow up after parasite
learance. There is little difference positive predictive values of positive
lms are consistently higher after treatment.
itaemia thresholds are shown in Fig. 1. Although sensitivity
nd specificity curves generated by the model were simi-
ar, the MAFFs calculated among all children with positive
lood films were greater after curative treatment, particularly
t lower parasitaemia thresholds.
Pre-treatment, there were 74 febrile parasitaemic children
ver 12 weeks of monitoring. An MAFF of 37% (95% CI
6–48%) among all parasitaemic children suggests that there
ere only 27 true episodes of malaria among these children
i.e. 2.3 week−1).
Malaria transmission was highest during the post-
reatment rainy season. There were 107 febrile parasitaemic
hildren during 12 weeks, and since the MAFF (for all chil-
ren with parasitaemia) was 74% (95% CI 63–83%) this
uggests 80 true episodes of malaria (i.e. 6.7 week−1).
During the 24-week post-treatment dry season, there were
9 febrile parasitaemic children, and an MAFF (for all chil-
ren with parasitaemia) of 51% (95% CI 37–63%) suggests
hat 24 had true episodes of malaria (i.e. 1 week−1).
Thus, the MAFF for all parasitaemia children during the
ost-treatment dry season, 51% (95% CI 37–63%), was inter-
ediate between the MAFF during the pre-treatment period,
t 37% (95% CI 26–48%), and the MAFF seen during the
ost-treatment rainy season, at 74% (95% CI 63–83%).
Using a threshold of 2500 paras/l, the MAFFs were 52%
CI 35–69%), 87% (CI 73–87%) and 65% (CI 50–80%) pre-
reatment, post-treatment rainy season and post-treatment dry
eason, respectively.
. DiscussionA phase 2b randomized controlled trial to measure the
fficacy of a candidate malaria vaccine was conducted. In
ommon with many phase 2b trials in children, the primary
ndpoint was episodes of febrile malaria. The specificity of
cine 25
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he endpoint is critical to the accuracy of estimates of efficacy
n clinical trials. Curative drug treatment before monitoring
as used to clear asymptomatic parasitaemia before vacci-
ation was complete. It is unclear whether this is necessary
n vaccine studies, and there are recommendations to not do
o in studies of blood stage vaccines [16]. In this analysis we
ave examined the impact this had on case definitions.
.1. Malaria attributable fever fractions varied
ollowing treatment
The logistic regression model (Fig. 1) suggested that
efore drug clearance the malaria attributable fever frac-
ions (MAFFs) were low. A threshold of 50,000 paras/l
ould be required for a case definition with a 90% MAFF
re-treatment. For a threshold of 2500 paras/l, the MAFF
as only 52%. Post-treatment, during the rainy season, the
AFFs increased, to 75% for all parasitaemic children, and
7% above a threshold of 2500 paras/l. However, there was
ore intense malaria transmission during this time period
6.7 cases/week versus 2.3 cases/week pre-treatment). It is
ifficult to judge how much of the increase in the case
efinition is due to rising malaria transmission, and how
uch due to the treatment of asymptomatic parasitaemia.
owever, malaria transmission was very low during the post-
reatment dry season, at 1 case/week. This was associated
ith a fall in MAFFs, but not to the pre-treatment levels.
lthough the difference between post-treatment rainy and
ry season shows that transmission intensity influences the
AFF, transmission was higher during pre-treatment than
t was for post-treatment dry season (2.3 cases/week versus
case/week). Despite a much higher transmission inten-
ity pre-treatment, the post-treatment dry season MAFFs
ere higher. Thus, both transmission intensity and the
requency of asymptomatic parasitaemia influenced the
AFFs.
The sensitivities and specificity plots against parasitaemia
ere similar before and after parasite clearance (Fig. 1), even
hough the MAFF among children with positive blood films
aried considerably. Sensitivity and specificity are proper-
ies intrinsic to the performance of the test, but the MAFF
epends on sensitivity, specificity and the pre-test probabil-
ty. The pre-test probability that parasitaemia indicated febrile
alaria, and not asymptomatic parasitaemia, had been altered
y drug clearance. The higher MAFF increases the accuracy
nd power of the study after clearance.
.2. Predicted impact on trial results
A standard power calculation suggests that if vaccine effi-
acy was 50%, a trial with 90% power would require 85
ubjects in each arm, given the rates of malaria seen here.
ow can one account for the situation where the MAFF is
nly 50%? If one assumes that the vaccine prevents fever
ausally related to parasitaemia, but not non-malaria fever
hat coincides by chance with asymptomatic parasitaemia,
r
i
d
b(2007) 8198–8202 8201
hen the apparent vaccine efficacy would be 25%, and the
equired sample size would be 265 subjects in each arm.
One could introduce a parasitaemia threshold to the case
efinition, in order to exclude cases of asymptomatic par-
sitaemia. However, this inevitably excludes some genuine
ases of febrile malaria with low parasitaemia, and so the
hosen threshold is a compromise between sensitivity and
pecificity. This then has the effect of increasing the sample
ize.
In our data, a case definition of any parasitaemia occurred
t an incidence of 0.55 per subject, but the MAFF was 36%
i.e. fever was causally related to parasitaemia in 36% of
he cases so defined). This would have required 512 sub-
ects per arm to detect 50% protection with 90% power.
t 50,000 paras/l 485 subjects per arm would be required
because of increased specificity). However, higher para-
itaemia thresholds do not result in further reductions in
ample size, because of the competing effect of lowered sensi-
ivity. At 100,000 paras/l, 578 subjects per arm are required.
However, after drug clearance, the MAFF rose to 0.64,
ithout any loss in sensitivity. This would require 158 sub-
ects per arm. Optimal power after drug clearance would have
een seen using a threshold of only 100 paras/l (143 subjects
er arm) and the sample size required would rise to 217 per
rm at 5000 paras/l.
Models have been used to demonstrate the theoretical
nderestimates and overestimates of blood stage vaccine effi-
acy against febrile malaria [14]. Our data suggest that more
ccurate estimates of efficacy in the field might be obtained
ollowing clearance of asymptomatic parasitaemia. In one
tudy of a blood stage vaccine, greater efficacy was observed
n the cohort of children without clearance of asymptomatic
arasitaemia [4], but this was primarily a reduction in para-
ite density rather than numbers of febrile episodes. However,
ntermittent presumptive treatment has been extensively stud-
ed [9], and using antimalarials prior to monitoring may
educe subsequent rates of febrile malaria. This impact must
e balanced against the possibility of reduced specificity lead-
ng to a biased, lower estimate of vaccine efficacy.
In recent studies of an efficacious vaccine [1,17] there
as no obvious difference in the point estimates of efficacy
sing varying parasitaemia thresholds. However, the vaccine
ad similar efficacy against asymptomatic parasitaemia and
ebrile malaria. Therefore, a child with non-malarial fever
ho had received the vaccine would be less likely to have
symptomatic parasitaemia giving rise to a spurious diag-
osis of malaria. This explains the consistent measures of
accine efficacy seen at varying parasite densities, since the
accinated children had lower rates of “true” febrile malaria
nd lower rates of “false positive” febrile malaria. In certain
cenarios this effect might lead to an overestimate of vaccine
fficacy, for instance if a vaccine was efficacious during a
ainy season, and monitoring of efficacy then continued dur-
ng a following dry season. The majority of cases identified
uring the low transmission of the dry season might actually
e coincident non-malarial fever and chronic asymptomatic
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arasitaemia acquired during the preceding rainy season. If
he prevalence of asymptomatic parasitaemia was lower at the
tart of the dry season among vaccinated children (because
f protection against asymptomatic parasitaemia during the
ainy season), then the apparent efficacy during ongoing mon-
toring would be overestimated. It would be predicted that
AFFs would demonstrate this effect, and it is therefore par-
icularly important that MAFFs are calculated separately for
ntervention groups, and by different time periods if waning
fficacy is a possibility.
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